Interestingly, given preclinical data showing bortezomib and vorinostat (histone deacetylase inhibitor) to be novel active agents in primary KMT2A rearranged (KMT2A-r) infant ALL, the SJCHR also carried out the Total Therapy for Infants with Acute Lymphoblastic Leukemia I study (TINI 1), which incorporated these two agents into an ALL chemotherapy backbone containing dexamethasone, mitoxantrone, and peg-asparaginase during induction and reinduction chemotherapy cycles (NCT02553460). Here, PAEP is linked to acute lymphoblastic leukemia.